09.04.2008 at 08:00
- Category:
Cancer and Oncology
Current study results from the report, 'Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts,' have been published. "Pancreatic ductal adenocarcinoma (ie, pancreatic cancer) is among the most devastating of human malignancies. It is commonly diagnosed at advanced, already metastatic, and, hence, incurable stages," investigators in the United States report.
"Despite extensive research efforts in recent decades, pancreatic cancer remains resistant to almost all clinically available therapy regimens. Recent advances in our understanding of the underlying pathophysiology and molecular biology have opened up avenues for the development of novel diagnostic and therapeutic strategies, some of which have shown highly promising preclinical results and are currently being translated into clinical application," wrote G. Feldmann and colleagues, Johns Hopkins University, Sol Goldman Pancreatic Cancer Research Center.
The researchers concluded: "Here in we present a review of recent literature on the molecular genetics of pancreatic cancer and emphasize clinical implications for the development of novel diagnostic and therapeutic approaches."
Feldmann and colleagues published their study in the Journal of Molecular Diagnostics (Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. Journal of Molecular Diagnostics, 2008;10(2):111-22).
For additional information, contact G. Feldmann, The Sol Goldman Pancreatic Cancer Research Center, Dept. of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231 USA..
The publisher of the Journal of Molecular Diagnostics can be contacted at: American Society Investigative Pathology, Inc., 9650 Rockville Pike, Bethesda, MD 20814-3993, USA.
Copyright 2008, Gastroenterology Week via NewsRx.com
